These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 10071548)

  • 21. Safety, efficacy and impact on Patients' quality of life of a long-term treatment with the alpha(1)-blocker alfuzosin in symptomatic patients with BPH. The Italian Alfuzosin Co-Operative Group.
    Eur Urol; 2000 Jun; 37(6):680-6. PubMed ID: 10828668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group.
    Buzelin JM; Fonteyne E; Kontturi M; Witjes WP; Khan A
    Br J Urol; 1997 Oct; 80(4):597-605. PubMed ID: 9352699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia.
    Marks LS; Roehrborn CG; Gittelman M; Kim D; Forrest J; Jacobs S
    Urology; 2003 Nov; 62(5):888-93. PubMed ID: 14624914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study.
    van Kerrebroec P; Jardin A; van Cangh P; Laval KU;
    Eur Urol; 2002 Jan; 41(1):54-60; discussion 60-1. PubMed ID: 11999466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin.
    McNeill SA; Hargreave TB; Geffriaud-Ricouard C; Santoni J; Roehrborn CG
    Urology; 2001 Mar; 57(3):459-65. PubMed ID: 11248620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia.
    Grasso M; Montesano A; Buonaguidi A; Castelli M; Lania C; Rigatti P; Rocco F; Cesana BM; Borghi C
    Arch Esp Urol; 1995; 48(1):97-103. PubMed ID: 7537488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
    Nordling J
    BJU Int; 2005 May; 95(7):1006-12. PubMed ID: 15839922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intermittent alpha-blocker therapy in the treatment of men with lower urinary tract symptoms.
    Kaplan SA; Reis RB; Cologna A; Suaid HJ; Martins AC; Kohn IJ; Te AE
    Urology; 1998 Jul; 52(1):12-6. PubMed ID: 9671862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of alfuzosin 10 mg once daily in the treatment of symptomatic benign prostatic hyperplasia.
    Kuritzky L; Rosenberg MT; Sadovsky R
    Int J Clin Pract; 2006 Mar; 60(3):351-8. PubMed ID: 16494652
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical uroselectivity: evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction.
    Buzelin JM; Delauche-Cavallier MC; Roth S; Geffriaud-Ricouard C; Santoni JP
    Br J Urol; 1997 Jun; 79(6):898-904; discussion 904-6. PubMed ID: 9202556
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Narayan P; Evans CP; Moon T
    J Urol; 2003 Aug; 170(2 Pt 1):498-502. PubMed ID: 12853808
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.
    Roehrborn CG; Van Kerrebroeck P; Nordling J
    BJU Int; 2003 Aug; 92(3):257-61. PubMed ID: 12887479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The treatment of patients with benign prostatic hyperplasia using the selective alpha-blocker alfuzosin].
    Mazo EB; Matushevskiĭ IA; Nikitin IuIu
    Ter Arkh; 1997; 69(10):79-82. PubMed ID: 9471799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A double-blind trial on the effect of alpha-adrenergic blocker (bunazosin hydrochloride) in the symptomatic treatment of prostatism].
    Kumamoto Y; Yokoyama E; Tsukamoto T; Tsuchida S; Nishizawa O; Koshiba K; Ishibashi A; Ogawa A; Tomita Y; Aso Y
    Hinyokika Kiyo; 1987 Oct; 33(10):1681-702. PubMed ID: 2451409
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia.
    McKeage K; Plosker GL
    Drugs; 2002; 62(4):633-53. PubMed ID: 11893233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group.
    Debruyne FM; Jardin A; Colloi D; Resel L; Witjes WP; Delauche-Cavallier MC; McCarthy C; Geffriaud-Ricouard C
    Eur Urol; 1998 Sep; 34(3):169-75. PubMed ID: 9732187
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effectiveness of various alfuzosin schedules in patients with benign prostatic hyperplasia (BPH)].
    Loran OB; Rasner PI; Kosko D; Pushkar' DIu
    Urologiia; 2001; (1):8-10. PubMed ID: 11233234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker.
    Roehrborn CG
    Urology; 2001 Dec; 58(6 Suppl 1):55-63; discussion 63-4. PubMed ID: 11750253
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Elhilali MM
    Expert Opin Pharmacother; 2006 Apr; 7(5):583-96. PubMed ID: 16553574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study.
    McNeill SA; Hargreave TB; Roehrborn CG;
    Urology; 2005 Jan; 65(1):83-9; discussion 89-90. PubMed ID: 15667868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.